is bpc-157 legal fda warning FDA's Overreach on Compounded Peptides Regeneration or Risk? A Narrative
Description
But you do not feel better
The key variables are patent expiration dates (by type), regulatory exclusivity expiration, the number and quality of Paragraph IV filers, litigation outcome probabilities, and the timing of 180-day exclusivity periods for the first generic filer
Here's the science
doi: 10.1001/jamapsychiatry.2015.0071
